Ocugen Inc (OCGN)
$2.06
0. (0.00%)
OCGN Stock Quote Delayed 30 Minutes
The Top Reasons to Avoid the Ocugen Stock
WIth Ocugen, there’s nothing to get excited about here. Avoid the OCGN stock, as it heads significantly lower.
11 Best Stocks to Buy for 2022
He found Apple at $1.49... Oracle at $0.51... Amazon at $46. Now, investing legend Louis Navellier is revealing his Top 11 Stocks for 2022 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
409.44M
PE Ratio
-6.06
EPS
-0.34
Volume (Avg. Vol.)
572
Day's Range
-
52-Week Range
$1.67 - $17.65
Dividend & Yield
N/A (N/A)
OCGN Stock Predictions, Articles, and Ocugen Inc News
It’s Time to Get Clinical, Not Cynical, With Ocugen Stock
The selling pressure on OCGN stock has been as heavy as a rock, but worried shareholders should celebrate Ocugen's breakthrough moments.
Why Is Ocugen (OCGN) Stock Up 10% Today?
Sometimes, improved investor sentiment and a revamped website is enough of a catalyst to take something like OCGN stock on a 10% ride higher.
The Biggest Reasons to Avoid Ocugen for Now
Ocugen was once one of the hottest stocks on the market. After soaring from 18 cents to $17.6 back to about $2.5. I simply wouldn’t touch it.
Why Is Ocugen (OCGN) Stock Up Today?
Biotechnology company Ocugen is grabbing headlines today after jumping more than 15%. Is OCGN stock making a comeback?
Ocugen Is Two Strikes in With a Third in the Books
Ocugen has tried repeatedly to bring drugs to market, first as Histogenics and later under its current name.
Why Is Ocugen (OCGN) Stock Down Today?
Shares of OCGN stock are in the red after the company's Covaxin Covid-19 vaccine was declined EUA by the FDA. Here's what you should know.
Ocugen Latest News: What OCGN Stock Investors Need to Know About the FDA’s Covaxin Rejection
Ocugen (OCGN) stock is falling hard on Friday after the FDA rejected its Emergency Use Authorization request for Covaxin.
Is OCGN Stock a Buy After 20% Plunge? One Analyst Thinks It Can Go to $15.
Ocugen is down more than 20% after announcing a common stock offering. Could this possibly present a buying opportunity for OCGN stock?
OCGN Stock Alert: The $50 Million Reason Ocugen Is Tanking Today
After rising sharply in recent days, Ocugen shares are again falling on news that the company is issuing $50 million of common stock.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, trader! It's time for another busy day of investing with the biggest pre-market stock movers for Wednesday!
Ocugen Is Too Uncertain as Time Runs Out for Covaxin’s Approval
Ocugen's path to entry in the North American market is highly uncertain, making OCGN stock a remarkably risky bet at this point.
OCGN Stock Alert: Why Is Ocugen Heating Up Today?
Shares of OCGN stock are flying higher after the FDA lifted its clinical hold on Covaxin, the company's coronavirus drug candidate.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
With the long weekend over it's time to start another week of trading with the biggest pre-market stock movers for Tuesday!
Despite an 80% Drop, Ocugen Stock Is Still Too Pricey
Until the hype surrounding its Covid-19 vaccine candidate is no longer priced into shares, it's best to avoid OCGN stock.
Ocugen Stock Finally Sunk to Penny Status, But That Doesn’t Make It a Buy
An interview with Dr. Anthony Fauci about the Covaxin vaccine makes you wonder why investors have any interest in Ocugen and OCGN stock.
Americans’ Appetite for Vaccine Options Bodes Well for Ocugen
OCGN stock is definitely out of favor on Wall Street, but fresh poll data and an imminent R&D hub acquisition should spur some optimism.
Ocugen Stock Is a Fairy Tale in Need of a Happy Ending
If you’re investing in OCGN stock, you have to wonder: how much upside can FDA approval really give this beleaguered name?
Two Reasons to Skip Ocugen Stock Despite Some Good News
Ocugen was one of the most explosive stocks on the market, all thanks to its coronavirus vaccine, Covaxin. But don't rush to buy just yet.
With No Vaccine Approval, Ocugen Is the Definition of Dead Money
Holding out hope for a Covid vaccine approval that might never come, OCGN stock is too risky while the company has no revenue.
